Evommune (EVMN) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evommune is the larger company by market cap ($232.6 million vs $217.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | PLX |
|---|---|---|
| Share price | $6.41 | $2.70 |
| Market cap | $232.63M | $217.54M |
| 1-day change | +3.05% | -0.37% |
| YTD return | -62.56% | +50.56% |
| 1-year return | — | +8.40% |
| 5-year return | — | +120.33% |
| P/E ratio (TTM) | — | 11.74 |
| Forward P/E | — | 4.35 |
| EPS (TTM) | $-3.75 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $3.19 |
| 52-week low | $6.02 | $1.60 |
| Distance from 52-week high | -80.69% | -15.36% |
| Analyst consensus | buy | none |
| Avg. price target upside | +276.44% | +307.41% |
| Average volume | 697.98K | 739.97K |
| Shares outstanding | 36.29M | 80.57M |
| Employees | 48 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
EVMN vs PLX FAQ
Which is bigger, Evommune or Protalix BioTherapeutics (DE)?
Evommune (EVMN) is larger, with a market capitalization of $232.63M compared with $217.54M for Protalix BioTherapeutics (DE) (PLX).
Are Evommune and Protalix BioTherapeutics (DE) in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Evommune and Biotechnology: Biological Products (No Diagnostic Substances) for Protalix BioTherapeutics (DE).